VTx-002 – ALS treatment

• MNDA poster - Sogorb et al. (2022), VecTabs® and advanced human in-vitro models: Targeting TDP-43 aggregates and oxidized phosphocholines in amyotrophic lateral sclerosis

VTx-003 - HD treatment

• DHDRN presentation - Konstantinova (2023), Precision targeted therapies for neurodegenerative diseases

• HDF poster - Pasteuning et al. (2022), VecTabs®: Targeting misfolded and aggregated proteins with vectorized antibodies for the treatment of ALS and HD

Platform technology

• ESGCT Poster - Spits et al. (2022), Gene Therapy Mediated Targeted Protein Degradation in Neurodegenerative Disease Models

• ESGCT poster - Callego et al. (2022), Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases